Nordic Nanovector ASA
F:8NN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nordic Nanovector ASA
F:8NN
|
NO |
|
S
|
Smart Globe Holdings Ltd
HKEX:1481
|
HK |
|
P
|
Pimpinan Ehsan Bhd
KLSE:PEB
|
MY |
|
Marfrig Global Foods SA
BOVESPA:MRFG3
|
BR |
|
China Avionics Systems Co Ltd
SSE:600372
|
CN |
|
N
|
NP3 Fastigheter AB
STO:NP3
|
SE |
|
Ackroo Inc
XTSX:AKR
|
CA |
|
Muthoot Finance Ltd
NSE:MUTHOOTFIN
|
IN |
|
Western Mines Group Ltd
ASX:WMG
|
AU |
|
Investor AB
F:IVSD
|
SE |
|
Jinxin Fertility Group Ltd
HKEX:1951
|
CN |
|
R
|
Rumere Co Ltd
SZSE:301088
|
CN |
|
Perfect Medical Health Management Ltd
HKEX:1830
|
HK |
|
P
|
Premier Synthetics Ltd
BSE:509835
|
IN |
|
A
|
Aroundtown SA
XETRA:AT1
|
LU |
|
R
|
Riga Sugar Co Ltd
BSE:507508
|
IN |
|
Yoc AG
XETRA:YOC
|
DE |
|
Qingdao Huicheng Environmental Technology Group Co Ltd
SZSE:300779
|
CN |
Nordic Nanovector ASA
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 40 full-time employees. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 40 full-time employees. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
